Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous ABBV-154 in moderately to severely active rheumatoid arthritis was terminated, with results on adverse events and changes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABBV-154

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA) | Phase 2 | Status: TERMINATED | Results posted: 2024-10-08